Spin-offs and other holdings


In 2016, Evotec implemented a new strategy of taking equity in promising start-ups. With these investments, we can create significant additional upside potential for the future of Evotec. Taking equity is simply another way of driving our long established strategic idea of co-owning assets. Furthermore, Evotec will always have the possibility to even further invest in these companies to increase the potential future upside.

Topas Therapeutics

In March 2016, Evotec announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders. Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the EUR 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain the largest shareholder after the financing round.

The new company, Topas Therapeutics GmbH ("Topas"), aims to build a unique pipeline of clinical-stage development projects to treat autoimmune diseases. The proceeds of the Series A funding enable Topas to expand and accelerate its proprietary liver-based tolerance induction platform and to progress with its own product development efforts in multiple autoimmune and inflammatory indications. In August 2017, Topas signed a multi-year research and option agreement with Lilly focused on immune intolerance. In April 2018, Topas announced a multi-year collaboration with Boehringer Ingelheim in the field of antigen-specific tolerance induction.
In December 2019, Topas announced the start of a first Phase 1 trial with its programme TPM203 in pemphigus vulgaris.

In October 2020, Topas announced the closing of a € 22 m (~$ 26 m) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas’ existing investors. The funding will be used to advance the Company’s proprietary pipeline based on the Topas Particle Conjugates technology platform. This includes progressing Phase I programme TPM203, and bringing TPM501, Topas’ candidate for the treatment of celiac disease, into the clinic.

Here you can find more information about Topas.

Carrick Therapeutics

In October 2016, Evotec announced that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Evotec will invest up to $ 6 m towards Carrick's latest funding round. The total $ 95 m round was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Google Ventures (GV), Lightstone Ventures, and Evotec.
Carrick, headquartered in Dublin with R&D located in Oxford and Dublin has a clear vision for cancer patients: its mission is to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Instead of banking on a single compound or biological mechanism, Carrick is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. To support this mission Evotec will provide its full range of discovery and oncology services, through its discovery and pre-clinical platform. Carrick will progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates.

Carrick progressed its lead programme into Phase I clinical trials in November 2017.

Here you can find more information about Carrick.


In January 2017, Evotec announced that it will extend its existing relationship with Eternygen GmbH ("Eternygen") by becoming an investor in addition to being a pre-clinical drug discovery partner. Within a consortium of investors including VC Fonds Technologie Berlin, managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices, Epidarex and Evotec together will participate in Eternygen's latest funding round of EUR 8 m (approx. $ 8.3 m).

Eternygen, a privately owned metabolic diseases company based in Berlin, Germany, is focused on the sodium coupled citrate transporter ("NaCT"), a novel target which is also known as INDY ("I am Not Dead Yet"). INDY is a key regulator of energy metabolism that may be involved in the pathogenesis of nonalcoholic fatty liver disease ("NAFLD"), nonalcoholic steatohepatitis ("NASH"), diabetes and obesity. Eternygen will use the proceeds of the Series A funding to accelerate its small molecule NaCT inhibitors towards the selection of a pre-clinical lead candidate. Eternygen will rely on Evotec's best-in-class drug discovery platform and metabolic disease expertise to conduct all work to the selection of pre-clinical development candidate and possibly beyond.

In October 2020, Eternygen announced the first closing of its Series A2 funding round led by Evotec as the new anchor investor.

Here you can find more information about Eternygen.

Fibrocor Therapeutics

In January 2017, Evotec and Toronto Innovation Acceleration Partners ("TIAP", formerly MaRS Innovation) announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $ 2.8 m (approx. $ 2.1 m) financing, which includes cash from TIAP. Evotec will provide all drug discovery activities and will also receive an equity stake.
Fibrocor takes a new approach to understanding and treating fibrosis, bringing together clinical expertise and access to disease tissue with high-throughput molecular analysis infrastructure and expertise in clinically-predictive animal models of fibrosis.
The company is co-founded with leading academic and clinician scientists from world-class academic institutions in Toronto, including Dr Richard Gilbert MD, PhD, Canada Research Chair in Diabetic Complications and Head of Endocrinology at St. Michael's Hospital and Scientist with the hospital's Keenan Research Centre for Biomedical Science; Dr Darren Yuen, MD, PhD, Nephrologist with St. Michael's and Scientist with its Keenan Research Centre for Biomedical Science; and Dr Jeff Wrana, PhD, Senior Investigator at Lunenfeld-Tanenbaum Research Institute, Sinai Health System. The academic/clinical team is complemented by management and business development from TIAP and drug discovery and development services from Evotec.

In January 2019, Fibrocor announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications with Galapagos NV. Fibrocor received an upfront payment, and potentially is eligible for further milestone and royalty payments. In January 2020, Fibrocor announced an expansion of the alliance, with Galapagos receiving the exclusive option to inlicense a total of four additional novel target programmes and taking an equity stake in Fibrocor.

Here you can find more information about Fibrocor.

Facio Therapies

In June 2017, Evotec announced that it will make a strategic investment as part of Facio Therapies' ("Facio") 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy ("FSHD") community (Total volume: € 4.8 m). Evotec is extending its ongoing drug discovery partnership with Facio and will carry out all discovery work. Through this investment, Evotec enters the field of musculoskeletal diseases via a very focused programme in FSHD, a disease of substantial unmet medical need affecting an estimated 700,000 people worldwide.

Facio, a privately owned company based in Leiden, Netherlands, solely focuses on finding a safe, effective, and affordable cure for FSHD. FSHD is a progressive muscle-wasting disease and there is currently no treatment option available. The key event in FSHD is the undue expression of the so-called DUX4 protein in skeletal muscle, which leads to muscle atrophy and oxidative stress. Since 2015, Facio and Evotec have been collaborating to identify DUX4-repressing small-molecule compounds as a potential treatment to stop the progression of FSHD. Following successful in vivo proof-of-principle in October 2018, Facio is currently working towards selecting a pre-clinical candidate. As part of the partnership, drug discovery efforts performed at Evotec have been based on screening patient-derived primary cells in a high-throughput manner.

In July 2020, Facio announced the successful raise of € 11.7 m (approximately $ 13.2 m) in equity financing from existing and new investors from the FSHD community and from Evotec, Facio’s strategic drug discovery partner.

Here you can find more information about Facio.


In September 2017, Evotec and Exscientia Ltd ("Exscientia") announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia. Through this investment, Evotec became the first strategic shareholder in the UK-based company. Exscientia is focused on Artificial Intelligence ("AI")-driven drug discovery and design.

Exscientia and Evotec have cooperated since early 2016 to advance small molecules and bispecific small molecules in immuno-oncology. The ongoing success of this partnership was the basis for an expanded and deepened corporate relationship. Exscientia is the world leader in developing and applying AI approaches specifically to design new and better therapeutic molecules in a faster and more cost-effective manner. Exscientia's approach fuses the power of AI with the discovery experience of seasoned drug hunters and chemistry experts. Exscientia uses its funds to drive higher value partner programmes and expand discovery on its automated design platform.

In January 2019, Evotec announced an additional investment of approximately $ 6 m towards Exscientia’s Series B funding round (Series B), in which Exscientia raised a total of $ 26 m. Bristol Myers Squibb (formerly Celgene Corporation) and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round.

In May 2020, Evotec announced that the Company had participated in Exscientia's latest funding round (Series C) which raised a total of $ 60 m from the existing investors' consortium and new investor Novo Holdings AS.

In March 2021, Exscientia announced that funds managed by BlackRock joined the Company’s Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $ 100 m in funding.

In April 2021, Evotec and Exscientia announced that the most advanced asset arising from their joint venture with has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec. 
Exscientia will lead further clinical development of the molecule and Evotec will retain co-ownership rights throughout clinical development.

Exscientia has active collaborations with, amongst others, Bayer, Bristol Myers Squibb, GSK, Roche, Sanofi and Sumitomo Dainippon.

Here you can find more information about Exscientia.

Forge Therapeutics

In December 2016, Evotec and Forge announced a strategic alliance to advance its novel Gram-negative antibiotic programme targeting 'LpxC' for the treatment of bacterial infections including those caused by drug resistant 'superbugs'. LpxC has been recognised as an attractive antibacterial target for more than the past 15 years; however, a lack of suitable chemical starting points has hampered its progress. Forge has been applying its proprietary metal-binding pharmacophores ("MBP") library and processes and has been able to identify potent drugable inhibitors of LpxC. The alliance has been expanded in October 2017 with the launch of the BLACKSMITH platform to discover a broader range of therapeutics targeting metalloenzymes.

Evotec participated in financing rounds of Forge in 2017 and 2018.

In April 2019, Forge and Basilea entered into a research collaboration and license agreement to discover, develop, and commercialise novel antibiotic classes.
In March 2020, Forge announced a research collaboration and option agreement with Roche to license one of its novel antibiotics for the treatment of hospital-based lung infections.

Here you can find more information about Forge.  

Breakpoint Therapeutics

In July 2019, Evotec announced the formation of the spin-off company Breakpoint Therapeutics GmbH, a virtual biotech company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers. The company expects to deliver the first IND-ready drug in 2022.

The early stage funding amounting to € 30 m is covered by a renowned international investor consortium led by Medicxi, a life sciences-focused investment firm, Taiho Ventures, LLC (“Taiho”), the venture capital arm of Taiho Pharmaceutical, and Evotec. Evotec holds below 50% of the company and consolidates at equity accordingly.

Aeovian Pharmaceuticals

In October 2019, Evotec took part in Aeovian Pharmaceuticals' Series A financing round together with lead investors venBio Partners and Sofinnova Investments and co-investor Apollo Health Ventures. The $ 37 m financing round followed Aeovian's successful nomination of a pre-clinical development candidate from its drug discovery partnership with Evotec. 

Here you can find more information about Aeovian


In November 2019, Evotec announced the formation of NephThera, a new 50:50 joint venture with Vifor Pharma Group focusing on the discovery and development of novel nephrology therapeutics. NephThera aims to identify new targets for renal therapies, and sharpen existing product profiles of an innovative pipeline by analysing the clinical data provided by Evotec that is mining a unique UK kidney biobank, NURTuRE. 

Initial funding of € 25 m for pre-clinical development will be covered by Vifor Pharma so that multiple targets or candidates can be moved forward simultaneously. The use of Evotec’s proprietary PanHunter bioinformatics platform, combined with high-quality data sets from thousands of human kidney disease patients will lead to the discovery of a number of promising therapeutic options in the kidney disease space.

Immunitas Therapeutics

In November 2019, Evotec participated in Immunitas Therapeutics' Series A. The $ 39 m financing round was led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors.

Immunitas is a single cell genomics-based drug discovery company founded by Longwood Fund, and plans to use this funding to advance its first programs, monoclonal antibody therapeutics with single agent activity in preclinical models of oncology, to clinical studies.

Here you can find more information about Immunitas


In December 2019, Evotec announced an equity investment in Celmatix, Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics. Evotec was joined in the financing by new investor, the Life Sciences Innovation Fund as well as existing investors, including Topspin Fund.

Here you can find more information about Celmatix


In April 2020, Evotec and panCELLa Inc. announced that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa’s proprietary iPS cell lines “iACT Stealth Cells™”, which are genetically modified to prevent immune rejection of derived cell therapy products (“cloaking”). Furthermore, Evotec will also have access to a new-generation cloaking technology known as hypoimmunogenic cells. In addition, the “FailSafe™” mechanism effectively addresses a key challenge in iPSC-based cell therapy, potential tumour formation by residual undifferentiated cells. 

Evotec has made an investment to take a minority stake in panCELLa and has nominated Dr Andreas Scheel to join panCELLa’s supervisory board.

Also in April 2020, panCELLa extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the need for immune suppression of patients.

Here you can find more information about panCELLa


In April 2020, Evotec announced a strategic partnership and equity investment with leon-nanodrugs GmbH, the leading enabler of nanotechnology for the pharmaceutical industry. Leon’s proprietary technology is aimed at suspending active pharmaceutical ingredients (“APIs”) in especially tailored nanoparticles to enhance solubility, bioavailability and stability in order to improve drug efficacy and safety.

Under the terms of the agreement, Evotec will leverage leon’s proprietary technology through the Company’s API manufacturing and CMC capabilities. Evotec and leon will leverage their combined expertise in nano-medicine development services, providing clients with world-class, end-to-end opportunities.

Evotec has made a strategic investment in leon by leading the company’s successful Series B funding round and has nominated Enno Spillner to join leon’s peer-recognised supervisory board.

For further information on leon, please visit leon-nanodrugs.com

QUANTRO Therapeutics

In July 2020, Evotec announced a comprehensive partnership with the recently established academic spin-off QUANTRO Therapeutics GmbH (“QUANTRO”), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases.

Evotec will provide hit identification services for QUANTRO’s proprietary anti-tumour projects. Furthermore, Evotec joins Boehringer Ingelheim Venture Fund GmbH in QUANTRO’s seed financing round. Both companies have acquired equal minority stakes in QUANTRO. Evotec will be represented on QUANTRO’s Supervisory Board by Dr Dirk Ullmann.

For further information about QUANTRO Therapeutics, please visit www.quantro-tx.com.


In December 2020, Evotec and Sartorius announced that they have entered into a partnership with Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. 
Curexsys delivers a proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables the company to overcome a key hurdle in exosome preparation, i.e. remaining antibodies in the final preparation.
The collaboration combines Evotec’s industry-leading induced Pluripotent Stem Cell (“iPSC”) platform with Curexsys’ proprietary technology to selectively isolate exosomes. Sartorius will support Curexsys to set up a GMP-compliant and scalable manufacturing platform.

Evotec and Sartorius have formed a consortium to jointly invest in Curexsys’ € 8.2 m seed financing round with Evotec acquiring an equity stake of approx. 37% in Curexsys and Sartorius of approx. 21%.

Blacksmith Medicines

In January 2021, Blacksmith Medicines, a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced that it has secured seed funding and has entered into a research collaboration with Eli Lilly. Eli Lilly joins existing Blacksmith investors Evotec SE, MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics.

Under the terms of the research collaboration agreement, Blacksmith and Eli Lilly will collaborate on up to 5 human metalloenzyme targets. Blacksmith received an upfront payment and an investment from Eli Lilly in exchange for a convertible note and will be eligible for up to approximately $ 60 m per target in potential research, development and commercial milestones for a total potential deal size up to approximately $ 300 m.

For further information on Blacksmith, please visit www.blacksmithmedicines.com


In March 2021, Argobio SAS, a newly-created start-up studio dedicated to life sciences, announced its launch with 50 M€ of committed capital. Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research. 

Argobio will create and launch at least five ambitious biotech companies over the next five years sourcing innovative early-stage projects from renowned European academic research institutions. Argobio will focus on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. It will also look to develop promising platform technologies for therapeutic products. The investors will have the opportunity to invest in the biotech companies created by Argobio.

For further information on Argobio, please visit www.argobiostudio.com


In April 2021, Evotec announced that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches.

OxVax is developing an innovative cancer vaccine platform based on a unique and proprietary population of dendritic cells capable of inducing a potent anti-tumour immune response. The company's technology allows the bulk manufacture of these cells from donor blood derived stem cells. By ex vivo loading of these cells with tumour antigens, OxVax will be able to create a vaccine which can train the body to target and eliminate tumours.

Evotec’s investment is co-led by the South Korean-based venture capital company Lead Compass Investment.

For further information, please visit www.oxvax.uk.

Contact us


Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 Get in touch with our experts vCard